Combivir (AZT/3TC)

Combivir is a fixed-dose combination tablet comprising 150mg 3TC (lamivudine) and 300mg AZT (zidovudine) manufactured by GlaxoSmithKline. AZT and 3TC are both nucleoside reverse transcriptase inhibitors (NRTIs) that can reduce the amount of HIV in the body. Combivir was the first tablet to combine more than one anti-HIV drug .

The standard dose of Combivir is one tablet twice a day, with or without food, in combination with at least one other anti-HIV drug. It is licensed for use in adults and children over twelve years of age. Its European licence was granted in March 1998 and in the United States in September 1997.

Combivir was licensed following demonstration that it had similar anti-HIV effects to AZT (Retrovir) and 3TC (Epivir) taken separately, when they were combined with a protease inhibitor. In a study of 223 patients, success rates were similar in the two arms. However, fewer patients randomised to receive Combivir missed drug doses, probably due to the smaller number of pills that need to be taken every day.1 The efficacy of AZT and 3TC had already been demonstrated in previous studies.

Current European and US guidelines (Department of Health and Human Services) recommend Combivir as an alternative therapy for a nucleoside backbone.

For more information on AZT and 3TC, including side-effects, resistance and drug interactions, see AZT (zidovudine, Retrovir) and 3TC (lamivudine, Epivir).


  1. Eron JJ et al. Efficacy, safety and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 14: 671-681, 2000
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.